Non-Muscle Invasive Urothelial Carcinoma
Non-Muscle Invasive Urothelial Carcinoma
David Ambinder, MDJournal | November 22, 2022
The multicenter phase 3 randomized controlled PHOTO trial examined if blue light cystoscopy could improve patient outcomes.
Read More
David Ambinder, MDJournal | November 22, 2022
A study analyzing the safety and efficacy of large surface area microparticle docetaxel for NMIBC is reviewed.
David Ambinder, MDJournal | October 24, 2022
Researchers evaluated the safety and efficacy of intravesical pembrolizumab when in conjunction with intravesical BCG.
Leah LawrenceNon-Muscle Invasive Urothelial Carcinoma | October 18, 2022
Short-term intensive chemoresection, a nonsurgical treatment modality, treated recurrent NMIBC, reducing required procedures.
Cecilia BrownNon-Muscle Invasive Urothelial Carcinoma | August 8, 2022
The induction lymphocyte-to-monocyte ratio was associated with “better accuracy” and than the preoperative ratio.
Cecilia BrownNon-Muscle Invasive Urothelial Carcinoma | July 29, 2022
While BCG has been the standard adjuvant therapy for patients with high-risk NMIBC, a shortage has led to other regimens.
David Ambinder, MDJournal | July 27, 2022
The current standard of care for patients with high-grade NMIBC, intravesical Bacillus Calmette-Guérin, is discussed.
Cecilia BrownNon-Muscle Invasive Urothelial Carcinoma | July 26, 2022
Pathogenic variants were more common in patients who had high-grade NMIBC than in patients with low-grade NMIBC.
Advertisement
Advertisement